Photo Credit: BENCHAMAT/Shutterstock.com
Researchers from Fujian Normal University, Funzhou, China, have developed a nonâinvasive cancer detection strategy based on gold nanoparticle surface-enhanced raman spectroscopy (SERS) and affinity chromatography (1).
As one of the greatest health burdens across the globe, cancer and all its forms rightly garner a large amount of clinical research attention with non-invasive and early cancer diagnosis being widely touted as necessary elements towards an effective strategy to minimize deaths. This is for obvious reasons with non-invasive procedures being much easier to carry out on a mass scale and early detection greatly increasing survival rates in most cancer cases. One area with potential is modified nucleosides, which are excreted through patient urine. An important biological matrix for determining a patient’s physical state, urinalysis is widely used in disease diagnosis. Its ease of collection aides in its usefulness as well as its ability to be continuously collected throughout an entire treatment process. However, urinary modified nucleosides are present at very low concentrations and their detection in such a complex matrix represents a significant challenge.
To achieve the necessary levels of sensitivity researchers first used affinity chromatography using a phenylboronic acid gel before analyzing samples using SERS and gold nanoparticles as a substrate.
To evaluate the utility of this method, urine samples from three groups of subjects were tested. These included nasopharyngeal cancer patients, esophaegeal cancer patients, and healthy volunteers. Results achieved diagnostic sensitivities above 90% and specificities above 95%, respectively. These results demonstrated the potential of this technique for non-invasive and label-free cancer detection and screening, with researchers currently conducting an inâdepth prospective study to verify the reliability of this new cancer detection method.
Reference
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.